These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 34371384)

  • 1. Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge.
    Bono M; Fanale D; Incorvaia L; Cancelliere D; Fiorino A; Calò V; Dimino A; Filorizzo C; Corsini LR; Brando C; Madonia G; Cucinella A; Scalia R; Barraco N; Guadagni F; Pedone E; Badalamenti G; Russo A; Bazan V
    ESMO Open; 2021 Aug; 6(4):100235. PubMed ID: 34371384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the appropriate genetic testing criteria for breast cancer in the Chinese population?-Analysis of genetic and clinical features from a single cancer center database.
    Ni M; Wang F; Yang A; Shao Q; Xue C; Xia W; Xu F; Lin X; Huang J; Bi X; Hong R; Chen M; Zheng Q; Jiang K; Xie X; Tang J; Wang X; Yuan Z; Wang S; Shi Y; An X
    Cancer Med; 2023 Jun; 12(12):13019-13030. PubMed ID: 37096751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.
    Manchanda R; Sun L; Sobocan M; Rodriguez IV; Wei X; Kalra A; Oxley S; Sideris M; Fierheller CT; Morgan RD; Chandrasekaran D; Rust K; Spiliopoulou P; Miller RE; Crusz SM; Lockley M; Singh N; Faruqi A; Casey L; Brockbank E; Phadnis S; Mills-Baldock T; El-Khouly F; Jenkins LA; Wallace A; Ahmed M; Kumar A; Swisher EM; Gourley C; Norquist BM; Evans DG; Legood R
    J Natl Compr Canc Netw; 2024 Apr; 22(2D):. PubMed ID: 38866043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond
    Fanale D; Incorvaia L; Filorizzo C; Bono M; Fiorino A; Calò V; Brando C; Corsini LR; Barraco N; Badalamenti G; Russo A; Bazan V
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32854451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients.
    Isiklar AD; Aliyeva L; Yesilyurt A; Soyder A; Basaran G
    Breast Cancer Res Treat; 2023 Nov; 202(2):297-304. PubMed ID: 37615792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of High-to-Moderate Penetrance Genes on Genetic Testing: Looking over Breast Cancer.
    Turchiano A; Piglionica M; Martino S; Bagnulo R; Garganese A; De Luisi A; Chirulli S; Iacoviello M; Stasi M; Tabaku O; Meneleo E; Capurso M; Crocetta S; Lattarulo S; Krylovska Y; Lastella P; Forleo C; Stella A; Bukvic N; Simone C; Resta N
    Genes (Basel); 2023 Jul; 14(8):. PubMed ID: 37628581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
    Kraus C; Hoyer J; Vasileiou G; Wunderle M; Lux MP; Fasching PA; Krumbiegel M; Uebe S; Reuter M; Beckmann MW; Reis A
    Int J Cancer; 2017 Jan; 140(1):95-102. PubMed ID: 27616075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing.
    Tuncer SB; Celik B; Erciyas SK; Erdogan OS; Gültaslar BK; Odemis DA; Avsar M; Sen F; Saip PM; Yazici H
    Pathol Res Pract; 2024 Feb; 254():155075. PubMed ID: 38219492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical usefulness of NGS multi-gene panel testing in hereditary cancer analysis.
    Anaclerio F; Pilenzi L; Dell'Elice A; Ferrante R; Grossi S; Ferlito LM; Marinelli C; Gildetti S; Calabrese G; Stuppia L; Antonucci I
    Front Genet; 2023; 14():1060504. PubMed ID: 37065479
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.
    ElBiad O; Laraqui A; El Boukhrissi F; Mounjid C; Lamsisi M; Bajjou T; Elannaz H; Lahlou AI; Kouach J; Benchekroune K; Oukabli M; Chahdi H; Ennaji MM; Tanz R; Sbitti Y; Ichou M; Ennibi K; Badaoui B; Sekhsokh Y
    BMC Cancer; 2022 Feb; 22(1):208. PubMed ID: 35216584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of Pathogenic Germline Mutations in Early and Late Onset Familial Breast Cancer Patients Using Multi-Gene Panel Sequencing: An Egyptian Study.
    Nassar A; Zekri AN; Kamel MM; Elberry MH; Lotfy MM; Seadawy MG; Hassan ZK; Soliman HK; Lymona AM; Youssef ASE
    Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
    Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
    J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A recurrent pathogenic BRCA2 exon 5-11 duplication in the Christian Arab population in Israel.
    Reznick Levi G; Larom G; Ofen Glassner V; Ekhilevitch N; Sharon Swartzman N; Paperna T; Baris-Feldman H; Weiss K
    Fam Cancer; 2022 Jul; 21(3):289-294. PubMed ID: 33999380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterization of ATM founder mutation in BRCA-negative breast cancer patients of Arab ethnicity.
    Bu R; Siraj AK; Al-Rasheed M; Iqbal K; Azam S; Qadri Z; Haqawi W; Tulbah A; Al-Dayel F; Almalik O; Al-Kuraya KS
    Sci Rep; 2023 Nov; 13(1):20924. PubMed ID: 38017116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
    Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
    BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis.
    Sandoval RL; Leite ACR; Barbalho DM; Assad DX; Barroso R; Polidorio N; Dos Anjos CH; de Miranda AD; Ferreira ACSM; Fernandes GDS; Achatz MI
    PLoS One; 2021; 16(2):e0247363. PubMed ID: 33606809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy.
    Ghiorzo P; Pensotti V; Fornarini G; Sciallero S; Battistuzzi L; Belli F; Bonelli L; Borgonovo G; Bruno W; Gozza A; Gargiulo S; Mastracci L; Nasti S; Palmieri G; Papadia F; Pastorino L; Russo A; Savarino V; Varesco L; Bernard L; Bianchi Scarrà G;
    Fam Cancer; 2012 Mar; 11(1):41-7. PubMed ID: 21989927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: an Italian case-control study.
    Bucalo A; Conti G; Valentini V; Capalbo C; Bruselles A; Tartaglia M; Bonanni B; Calistri D; Coppa A; Cortesi L; Giannini G; Gismondi V; Manoukian S; Manzella L; Montagna M; Peterlongo P; Radice P; Russo A; Tibiletti MG; Turchetti D; Viel A; Zanna I; Palli D; Silvestri V; Ottini L
    Eur J Cancer; 2023 Jul; 188():183-191. PubMed ID: 37262986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
    Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
    Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.